Skip to main content


Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 6

Risk of MACE in the subgroup of patients with a history of CVD. (CVD history). Data presented by a the different types of CVD in patient history, and b the number of CVD event types in patient history. n is the number of patients with an event; N is the number of patients in treatment group. Coronary = coronary artery disease (myocardial infarction, hospitalisation for unstable angina, coronary artery bypass graft, percutaneous coronary intervention or stable angina); cerebrovascular = cerebrovascular disease (carotid artery disease, carotid endarterectomy or stenting, stroke or transient ischaemic attack); peripheral = peripheral vascular disease (amputation, peripheral vascular disease or peripheral vascular surgery). CHF congestive heart failure, CI confidence interval, CTRL control, CV cardiovascular, CVD CV disease, DAPA dapagliflozin, HR hazard ratio, MACE major adverse cardiovascular events (CV death, myocardial infarction and stroke), n/a not available, p–y = patient–years

Back to article page